Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 7/20 | 0.31 |
| ▸ | GSK3B | P49841 | 7/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25815465 | 0.84 | NLRP3 (0.33) | KDM4ENPC1ALDH1A1RAB9APRMT5 | |
| SCHEMBL23952352 | 0.83 | PARP1 (0.37) | KDM4ENPC1ALDH1A1RAB9AGAA | |
| SCHEMBL23952556 | 0.83 | MAPK14 (0.32) | KDM4ENPC1ALDH1A1RAB9APRMT5 | |
| SCHEMBL23952551 | 0.83 | NLRP3 (0.38) | KDM4ENPC1ALDH1A1RAB9AGAA | |
| SCHEMBL25816039 | 0.83 | PDE9A (0.32) | KDM4ENPC1ALDH1A1RAB9APRMT5 | |
| SCHEMBL23952549 | 0.83 | PDE5A (0.37) | KDM4ENPC1ALDH1A1RAB9APRMT5 | |
| SCHEMBL23925406 | 0.81 | PDE4B (0.33) | KDM4ENPC1ALDH1A1RAB9ATHRB | |
| SCHEMBL23952423 | 0.79 | PRMT5 (0.35) | PRMT5WDR77THRATHRB | |
| SCHEMBL23952164 | 0.79 | PRMT5 (0.32) | NPC1RAB9APRMT5WDR77 | |
| SCHEMBL23952434 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | KDM4E 3436/4885NPC1 2094/4885ALDH1A1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.